Publications
- Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma patients in the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Outcome of elderly patients with classical Hodgkin's lymphoma2020 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Konjugované monoklonální protilátky v léčbě lymfocytů2019 | First Faculty of Medicine
- Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy2018 | First Faculty of Medicine
- Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?2015 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Hodgkin's Lymhoma - the Treatment Aproaches Development and Current Trends2015 | First Faculty of Medicine
- Autologous stem cell transplantation for AL amyloidosis –single-center results of a strict risk-adapted approach.2010 | First Faculty of Medicine
- Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre2010 | First Faculty of Medicine
- Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre2010 | Publication without faculty affiliation
Loading network view...